OLFM4 / GW112 Antibody, Mouse MAb
  0 products, total $0.+86-400-890-9989      Login |  Register 中文한국어

Browse By Molecule:

Your Position: Home > Antibody > Mouse MAb Antibody > OLFM4 / GW112 Antibody, Mouse MAb

OLFM4 / GW112 Antibody, Mouse MAb PDF Download

Catalog   Size (Price) Quantity In Stock Operation


Primary antibody | Secondary antibody | Tag antibody | Isotype control antibody | Loading control antibody | Antibody Purification

OLFM4 / GW112 Antibody Datasheet

  Order or Inquire for OLFM4 / GW112 Antibody product Quality antibodies Antibody production services

OLFM4 / GW112 Antibody Product Information

Immunogen :

Recombinant Human OLFM4 / GW112 protein (Catalog#11639-H08H)

Antibody Type : Mouse Monoclonal Antibody ( Mouse mAb Service Platform )

Clone ID :


Ig Type :

Mouse IgG1

Formulation : 0.2 μm filtered solution in PBS, 5% trehalose may be added in some batches. Please read the hardcopy of COA or contact our customer service to confirm the formulation.
Preparation :

This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human OLFM4 / GW112 (rh OLFM4 / GW112; Catalog#11639-H08H; NP_006409.3; Met 1-Gln 510).

OLFM4 / GW112 Antibody Usage Guide

Specificity :

Human OLFM4 / GW112

Flow Cytometry :
OLFM4 / GW112 Flow Cytometry

Flow cytometric analysis of Human OLFM4 expression in DU145 cells. The cells were treated according to manufacturer's manual (BD Pharmingen™ Cat. No. 554714), and stained with Purified Mouse anti-OLFM4 (11639-MM12, 1 μg/test), then a FITC-conjugated second step antibody. The fluorescence histograms were derived from gated events with the forward and side light-scatter characteristics of intact cells.

Flow cytometry was performed on a BD FACSCalibur flow cytometry system

Please refer to www.sinobiological.com/Flow-Cytometry-FACS-Protocols-a-750.html for technical protocols.

Direct ELISA : This antibody can be used at 0.5-1 μg/mL with the appropriate secondary reagents to detect Human OLFM4.
Storage : This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -70℃. Preservative-Free.
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.

OLFM4 / GW112 Antibody Related Products & Topics

OLFM4 / GW112 Antibody Related Areas:

Cancer>>Cancer Biomarkers>>OLFM4/GW112


Molecule Species Description //For Detailed Info. and Price------CLICK! Cat. No
OLFM4/GW112 Human OLFM4/GW112 Protein, Recombinant 11639-H08H


Molecule Application Description //For Detailed Info. and Price------CLICK! Cat. No
Human OLFM4/GW112 WB, ELISA OLFM4 / GW112 Antibody 11639-MM02
Human OLFM4/GW112 ELISA, FCM OLFM4 / GW112 Antibody 11639-MM12

OLFM4 / GW112 Antibody Background

Olfactomedin-4, also known as G-CSF-stimulated clone 1 protein, Antiapoptotic protein GW112, and OLFM4, is a secreted protein which contains oneolfactomedin-like domain. OLFM4 is expressed during myeloid lineage development. It is strongly expressed in the prostate, small intestine and colon and moderately expressed in the bone marrow and stomach. OLFM4 is highly expressed in pancreatic cancer tissues and shows an elevated expression level during the early S phase of the cell cycle. It is also expressed at high levels in stomach cancer and colon cancer tissues. Inhibition of ROS or the ERK pathway remarkably decreased G-CSF-induced OLFM4 expression. OLFM4 is an antiapoptotic factor that promotes tumor growth. OLFM4 promotes proliferation of pancreatic cancer cells by favoring the transition from the S to G2/M phase. OLFM4 also facilitates cell adhesion. Induction of OLFM4 in cancer cells was reported to have a novel antiapoptotic action via binding to the potent apoptosis inducer GRIM-19. The human OLFM4 is also thought to be a useful marker for early myeloid development.


  1. Zhang J., et al., 2002, Gene 283: 83-93.
  2. Zhang X., et al., 2004, Cancer Res. 64: 2474-2481.
  3. Kobayashi D., 2007, et al., Cancer Sci. 98: 334-340.
  4. Kobayashi, D.et al., 2007, Cancer Sci. 98 (3): 334-40.
  5. van der Flier, L.G. et al., 2009, Gastroenterology. 137 (1): 15-7.


Primary Antibody Products